Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Hyperkalemia

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Hyperkalemia

Leslie V. Simon et al.
Free Books & Documents

Excerpt

Hyperkalemia is a condition marked by a serum or plasma potassium concentration exceeding the upper limit of normal, typically greater than 5.0 to 5.5 mEq/L. Mild elevations are often asymptomatic, whereas severe hyperkalemia can precipitate life-threatening cardiac arrhythmias, muscle weakness, or paralysis. Clinical manifestations generally appear at levels above 6.0 mEq/L. However, the rate of change exerts greater influence than absolute values. Patients with chronic hyperkalemia, such as those with renal impairment, may tolerate higher potassium concentrations without symptoms, whereas acute shifts in potassium can induce severe manifestations at lower levels. Baseline potassium concentrations are higher in infants compared with children and adults.

Pseudohyperkalemia is a spurious elevation in measured potassium, commonly resulting from specimen collection, handling, hemolysis, or thrombocytosis. Serum potassium should be confirmed prior to the initiation of aggressive therapy when elevations lack a clear explanation. True hyperkalemia arises from increased potassium intake, transcellular shifts of intracellular potassium, or impaired renal excretion. Therapeutic urgency is determined by the severity of clinical manifestations, measured potassium levels, and underlying etiology.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Leslie Simon declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Rout declares no relevant financial relationships with ineligible companies.

References

    1. Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ. Mineralocorticoid Antagonism and Diabetic Kidney Disease. Curr Diab Rep. 2019 Jan 23;19(1):4. - PubMed
    1. Flury G. [The 'Dangerous' ECG]. Praxis (Bern 1994) 2019 Jan;108(1):45-52. - PubMed
    1. Fujimaru T, Hirose K, Yazawa M, Nagahama M, Kovesdy CP, Electrolyte Winter Seminar Collaborative Group Pathophysiology and causes of hyperkalemia: unraveling causes beyond kidney dysfunction. Clin Exp Nephrol. 2025 Nov;29(11):1524-1534. - PMC - PubMed
    1. Williams SM, Killeen AA. Tumor Lysis Syndrome. Arch Pathol Lab Med. 2019 Mar;143(3):386-393. - PubMed
    1. Dunn JD, Benton WW, Orozco-Torrentera E, Adamson RT. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015 Nov;21(15 Suppl):s307-15. - PubMed

Publication types

LinkOut - more resources